CICC Research Begins Coverage on Intuitive Surgical (NASDAQ:ISRG)

CICC Research initiated coverage on shares of Intuitive Surgical (NASDAQ:ISRGFree Report) in a research note issued to investors on Monday. The firm issued a neutral rating and a $550.00 price objective on the medical equipment provider’s stock.

A number of other equities research analysts have also commented on ISRG. Mizuho upped their price target on Intuitive Surgical from $440.00 to $500.00 in a research report on Thursday, October 17th. Leerink Partners upped their target price on Intuitive Surgical from $490.00 to $548.00 in a report on Monday. Barclays increased their price target on Intuitive Surgical from $610.00 to $674.00 in a report on Monday. Wells Fargo & Company boosted their price objective on Intuitive Surgical from $630.00 to $687.00 and gave the company an “overweight” rating in a research note on Friday. Finally, JPMorgan Chase & Co. raised their target price on Intuitive Surgical from $575.00 to $675.00 and gave the stock an “overweight” rating in a research note on Friday. One equities research analyst has rated the stock with a sell rating, five have issued a hold rating and sixteen have assigned a buy rating to the company’s stock. According to data from MarketBeat, the company currently has a consensus rating of “Moderate Buy” and a consensus target price of $613.10.

Check Out Our Latest Stock Analysis on Intuitive Surgical

Intuitive Surgical Stock Performance

ISRG stock opened at $573.48 on Monday. The company has a market capitalization of $204.26 billion, a P/E ratio of 92.20, a PEG ratio of 5.19 and a beta of 1.39. The company has a fifty day moving average price of $547.16 and a 200-day moving average price of $505.21. Intuitive Surgical has a 52-week low of $364.17 and a 52-week high of $616.00.

Insider Transactions at Intuitive Surgical

In other Intuitive Surgical news, CEO Gary S. Guthart sold 18,151 shares of Intuitive Surgical stock in a transaction that occurred on Wednesday, October 30th. The shares were sold at an average price of $511.63, for a total transaction of $9,286,596.13. Following the transaction, the chief executive officer now owns 24,219 shares of the company’s stock, valued at $12,391,166.97. This trade represents a 42.84 % decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. Also, CFO Jamie Samath sold 108 shares of the company’s stock in a transaction that occurred on Tuesday, November 26th. The shares were sold at an average price of $542.06, for a total value of $58,542.48. Following the completion of the transaction, the chief financial officer now directly owns 8,757 shares of the company’s stock, valued at approximately $4,746,819.42. This represents a 1.22 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold a total of 42,265 shares of company stock valued at $21,964,281 over the last ninety days. 0.90% of the stock is currently owned by insiders.

Institutional Inflows and Outflows

A number of institutional investors have recently bought and sold shares of the business. Berbice Capital Management LLC bought a new position in Intuitive Surgical during the fourth quarter valued at $26,000. Godsey & Gibb Inc. grew its stake in shares of Intuitive Surgical by 140.0% during the 3rd quarter. Godsey & Gibb Inc. now owns 60 shares of the medical equipment provider’s stock worth $29,000 after acquiring an additional 35 shares during the period. MidAtlantic Capital Management Inc. purchased a new stake in Intuitive Surgical in the 3rd quarter worth about $33,000. Decker Retirement Planning Inc. bought a new position in Intuitive Surgical during the fourth quarter worth about $36,000. Finally, Capital Performance Advisors LLP purchased a new position in shares of Intuitive Surgical in the third quarter worth about $38,000. Institutional investors own 83.64% of the company’s stock.

About Intuitive Surgical

(Get Free Report)

Intuitive Surgical, Inc develops, manufactures, and markets products that enable physicians and healthcare providers to enhance the quality of and access to minimally invasive care in the United States and internationally. The company offers the da Vinci Surgical System that enables complex surgery using a minimally invasive approach; and Ion endoluminal system, which extends its commercial offerings beyond surgery into diagnostic procedures enabling minimally invasive biopsies in the lung.

Read More

Analyst Recommendations for Intuitive Surgical (NASDAQ:ISRG)

Receive News & Ratings for Intuitive Surgical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Intuitive Surgical and related companies with MarketBeat.com's FREE daily email newsletter.